相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
Amer M. Zeidan et al.
BLOOD (2022)
Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST Study
Uwe Platzbecker et al.
BLOOD (2021)
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Fenaux et al.
ANNALS OF ONCOLOGY (2021)
How we manage adults with myelodysplastic syndrome
Pierre Fenaux et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Therapy for lower-risk MDS
Hetty E. Carraway et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review
Sophie Park et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
分享论文
